- Home
- BLUE vs RVPHW Comparison
BLUE vs RVPHW Comparison
Compare BLUE & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLUE
- RVPHW
- Stock Information
- Founded
- BLUE 1992
- RVPHW N/A
- Country
- BLUE United States
- RVPHW United States
- Employees
- BLUE N/A
- RVPHW 15
- Industry
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- BLUE Health Care
- RVPHW Health Care
- Exchange
- BLUE Nasdaq
- RVPHW Nasdaq
- Market Cap
- BLUE N/A
- RVPHW N/A
- IPO Year
- BLUE 2013
- RVPHW 2018
- Fundamental
- Price
- BLUE $0.50
- RVPHW $0.14
- Analyst Decision
- BLUE Hold
- RVPHW
- Analyst Count
- BLUE 11
- RVPHW 0
- Target Price
- BLUE $4.74
- RVPHW N/A
- AVG Volume (30 Days)
- BLUE 7.7M
- RVPHW N/A
- Earning Date
- BLUE 11-05-2024
- RVPHW N/A
- Dividend Yield
- BLUE N/A
- RVPHW N/A
- EPS Growth
- BLUE N/A
- RVPHW N/A
- EPS
- BLUE N/A
- RVPHW N/A
- Revenue
- BLUE $45,689,000.00
- RVPHW N/A
- Revenue This Year
- BLUE $816.57
- RVPHW N/A
- Revenue Next Year
- BLUE $219.94
- RVPHW N/A
- P/E Ratio
- BLUE N/A
- RVPHW N/A
- Revenue Growth
- BLUE 1032.88
- RVPHW N/A
- 52 Week Low
- BLUE $0.48
- RVPHW N/A
- 52 Week High
- BLUE $5.53
- RVPHW N/A
- Technical
- Relative Strength Index (RSI)
- BLUE 32.06
- RVPHW N/A
- Support Level
- BLUE $0.54
- RVPHW N/A
- Resistance Level
- BLUE $0.75
- RVPHW N/A
- Average True Range (ATR)
- BLUE 0.05
- RVPHW 0.00
- MACD
- BLUE 0.01
- RVPHW 0.00
- Stochastic Oscillator
- BLUE 11.17
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.